Trial Profile
Safety and Effect of Elbasvir/Grazoprevir Combination Therapy in Hemodialysis Patients With Chronic Hepatitis C
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 May 2022
Price :
$35
*
At a glance
- Drugs Elbasvir/grazoprevir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 21 Jan 2017 Status changed to recruiting.
- 19 Jan 2017 New trial record